MENU
+Compare
BBP
ETF ticker: NYSE ARCA
AS OF
Jul 3 closing price
Price
$59.73
Change
+$0.30 (+0.50%)
Net Assets
23.79M

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BBP with price predictions
Jul 03, 2025

BBP in upward trend: price rose above 50-day moving average on June 02, 2025

BBP moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend. In of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on BBP as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for BBP crossed bullishly above the 50-day moving average on June 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 208 cases where BBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BBP moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for BBP turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

BBP broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 12.33B. The market cap for tickers in the group ranges from 194.77M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is YMAB at 194.77M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 2%. For the same ETF, the average monthly price growth was 2%, and the average quarterly price growth was -2%. ARDX experienced the highest price growth at 16%, while AUPH experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was -31%. For the same stocks of the ETF, the average monthly volume growth was -52% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 77
Price Growth Rating: 55
SMR Rating: 82
Profit Risk Rating: 79
Seasonality Score: -14 (-100 ... +100)
View a ticker or compare two or three
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
501 Madison Avenue, Suite 501New YorkNew York
Phone
(212) 593-4383
Web
N/A